14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
PACB vs PMI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Picard Medical, Inc. (PMI) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 60.7/100 (BUY) at $1.76 (N/M Forward P/E, -333.0% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).
Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (60.7/100 BUY vs. PMI 48.4/100 HOLD), PMI captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-248.1% vs. -333.0% operating margin) and revenue trajectory (+38.6% vs. +5.5% YoY).
Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 38.5); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PACB vs PMI Key Questions & Quantitative Answers
As of Nov 19, 2026, Picard Medical, Inc. (PMI) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PACB carries a Unified Composite Score of 60.7/100 (BUY) at $1.76 (N/M Forward P/E, -333.0% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (60.7/100 BUY vs. PMI 48.4/100 HOLD), PMI captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-248.1% vs. -333.0% operating margin) and revenue trajectory (+38.6% vs. +5.5% YoY). Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 38.5); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PACB leads the Growth & Scale pillar: PACB posts +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PACB cumulative revenue shifted +100.0% while PMI shifted N/A. In operating R&D and SG&A reinvestment, PACB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.
PMI screens cheaper on headline valuation multiples. PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.6x EV/Revenue (-93.2% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACB (-929.3% ROE) versus PMI (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, PACB carries 191.0% implied volatility (97th %ile, Extreme (>80th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.27β · 103% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.